effects of glp-1 receptor agonists on neurological complications of diabetes as Treatments for Type 2 GLP-1 receptor agonists in neurological
Description
The year delivered progress across clinical evidence, policy, and changing market dimensions, reinforcing obesity as a chronic disease requiring structured, long-term management
Key milestones highlighted in this timeline: 1999 Orlistat (Xenical) The first long-term FDA-approved anti-obesity medication of the modern era
GLP-1 generics enter the worlds diabetes capital and are added to bridal packages to cut food noise
Explore the differences in GLP-1 patches vs injections and pills
